Drug Discovery & Pharmaceuticals

RSS

Scientists design breakthrough drug to combat deadly pancreatic cancer mutation

Scientists discover a new way to disarm a deadly protein that also appears in cancers of the lung, breast and colon.

5 Mar 2024

New class of antiviral drugs could shield against future viral outbreaks

A University of Alberta research team has uncovered a new class of drugs with the potential to prevent or treat infections in a future viral outbreak.

4 Mar 2024

UB research may offer a more streamlined approach to developing cancer drugs

Drug discovery can be a frustrating process of trial and error.

28 Feb 2024

ChatGPT aids in discovering potential Alzheimer’s treatments through drug repurposing

ChatGPT-4 to identify drug repurposing candidates against Alzheimer’s disease (AD).

28 Feb 2024

FB1006: AI-discovered drug advances to clinical trials for ALS treatment

Amyotrophic Lateral Sclerosis (ALS) is a fatal type of motor neuron disease characterized by progressive degeneration of nerve cells in the spinal cord and brain, resulting in muscle weakness and paralysis that can include the inability to walk and speak, or even swallow and breathe.

27 Feb 2024

Yale chemists synthesize complex anticancer molecules from marine invertebrates

Nearly 30 years ago, scientists discovered a unique class of anticancer molecules in a family of bryozoans, a phylum of marine invertebrates found in tropical waters.

22 Feb 2024

Selkirk Pharma announces new APS qualified facility with advanced fill/finish capacity in Spokane, WA

Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced the Aseptic Process Simulation (APS) qualification of its sterile manufacturing facility and newly available fill/finish capacity.

From Selkirk Pharma 22 Feb 2024

Collaborative project gets $20 million to develop new radiopharmaceutical cancer therapies

UT Health Science Center researchers Gabor Tigyi, MD, PhD, Harriet Van Vleet Endowment Professor in Basic Oncology Research, Junming Yue, PhD, associate professor in the Department of Pathology, Sue Chin Lee, PhD, in the Department of Physiology, and David Schwartz, MD, chair of the Department of Radiation Oncology, are part of a scientific leadership group awarded $20 million from the University of Tennessee-Oak Ridge Innovation Institute in partnership with Oak Ridge National Laboratory and the University of Tennessee, Knoxville, to develop new radiopharmaceutical therapies to treat cancer.

21 Feb 2024

Scripps Research scientists develop an antibody that blocks lethal snake toxins

Scripps Research scientists have developed an antibody that can block the effects of lethal toxins in the venoms of a wide variety of snakes found throughout Africa, Asia and Australia.

21 Feb 2024

Molecular glue could pave the way for new generation of drugs

A breakthrough class of molecular glue identified at the University of Dundee could pave the way for a new generation of drugs to target cancers and neurodegenerative diseases.

21 Feb 2024

Cellectricon’s expertise in pain research recognized by second EU research grant

BonePainIII project will support an early-stage researcher in quest for novel mechanistic insight and potential therapeutic targets.

From Cellectricon 19 Feb 2024

Novel synthetic antibiotic effective against drug-resistant bacteria

A new antibiotic created by Harvard researchers overcomes antimicrobial resistance mechanisms that have rendered many modern drugs ineffective and are driving a global public health crisis.

15 Feb 2024

Breaking through new research barriers with iPSC technology

In this interview, we speak to Keith Olson and Coby Carlson from Fujifilm Cellular Dynamics about their iPSC technology.

From FUJIFILM Cellular Dynamics 15 Feb 2024

Academia's drug discovery challenges: Exploring the "publication landfill"

A new editorial paper was published in Oncotarget's Volume 15 on January 24, 2024, entitled, "The fate of drug discovery in academia; dumping in the publication landfill?"

6 Feb 2024

Hamamatsu introduces the New FDSS-GX: the highest-performance kinetic plate imager in the FDSS series

Hamamatsu Photonics announces the release of a new high-speed kinetic plate imager, the FDSS-GX.

From Hamamatsu Photonics Europe 5 Feb 2024

SCIEX expands high-throughput screening solutions with Echoâ MS+ system

The Echo® MS+ system unlocks enhanced high-throughput screening capability by bringing acoustic ejection mass spectrometry (AEMS) approaches to the SCIEX ZenoTOF 7600 system.

From SCIEX 5 Feb 2024

Almirall and Microsoft partner on AI-powered drug discovery in dermatology

Almirall S.A., a global pharmaceutical company focused on medical dermatology, announced today a strategic partnership with Microsoft to drive innovation and digital transformation, advance the research of medical solutions for dermatological diseases, and accelerate the digital transformation of the company.

5 Feb 2024

New molecule is one step closer to becoming a treatment for Phelan-McDermid syndrome

A molecule created at the University of Auckland is one step closer to becoming a treatment for an extremely rare and severely debilitating neurological disorder called Phelan-McDermid syndrome.

2 Feb 2024

Researchers discover non-opioid therapeutic for relieving neuropathic pain

Among the most difficult types of pain to alleviate is neuropathic pain, pain that is usually caused by damage to nerves in various body tissues, including skin, muscle and joints.

31 Jan 2024

CN Bio appoints Joseph Parisi as US Director of Sales to support accelerated growth in key OOC market

CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced the appointment of Joseph Parisi as US Director of Sales. In his new role, Joe will lead the expansion of the Company’s sales and support activities for the US market to address the growing demand for new alternative methodologies (NAMs) in preclinical drug discovery.

31 Jan 2024